<DOC>
	<DOCNO>NCT00169104</DOCNO>
	<brief_summary>Trastuzumab Herceptin antibody direct Her-2 . Her-2 growth factor receptor present tumor 25 % patient breast cancer . The addition trastuzumab chemotherapy show randomized clinical trial increase response rate chemotherapy , duration response chemotherapy , improve duration survival patient metastatic breast cancer . The anticancer mechanism action trastuzumab unknown , possible trastuzumab act promote antibody-dependent cell mediate cytotoxicity ( ADCC ) , direct kill cancer cell immune cell , trigger antibody bound surface cancer cell . G-CSF drug growth factor certain type immune cell . G-CSF two favorable effect ADCC . G-CSF increase pool circulate cancer-killing immune cell , G-CSF increase strength bind cancer-killing immune cell specific part antibody . Therefore , prim G-CSF significantly increase efficiency ADCC , four day treatment G-CSF show optimize ADCC study . Recent data investigator ' laboratory indicate chemotherapy augment ADCC direct tumor cell . The investigator ' hypothesis pre-treatment drug G-CSF would increase effectiveness chemotherapy give trastuzumab .</brief_summary>
	<brief_title>Effects Granulocyte Colony-stimulating Factor ( G-CSF ) , Trastuzumab , Vinorelbine Immune Cell Function</brief_title>
	<detailed_description>This randomized phase II study compare trastuzumab G-CSF trastuzumab placebo first two week therapy . Twenty five patient metastatic breast cancer randomize receive weekly trastuzumab plus either G-CSF placebo subcutaneous ( SQ ) injection daily five day weekly two week . Subsequently , patient receive additional 12 week weekly trastuzumab , G-CSF SQ injection daily five day weekly 12 week , vinorelbine weekly dose 25 mg/m2 week 3 , 4 , 6 , 7 , 9 , 10 , 12 , 13 . Baseline evaluation include history physical exam , comprehensive metabolic panel ( CMP ) , complete blood count ( CBC ) , serum pregnancy test , computerize tomography ( CT ) scan disease measurement , Multiple Uptake Gated Acquisition ( MUGA ) scan . The CT scan MUGA repeat upon completion study treatment . Blood drawn pre-trastuzumab , 2 hour post-trastuzumab , 48 hour post-trastuzumab week 1 , 2 , 3 , 4 , 12 measure whole blood ADCC activity . Two additional assay whole blood ADCC activity drawn baseline pre-treatment , follow completion protocol treatment . These assay measure chromium release Her-2 positive target cell expose patient 's effector cell . Measurement soluble Her-2 patient serum also measure ADCC time point .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>All patient must pathological confirmation carcinoma breast . Patients must metastatic breast cancer document clinical radiological assessment . Immunohistochemical analysis HER2/neu expression paraffinembedded specimen perform . HER2/neu overexpression qualitatively score 0 , 1+ , 2+ , 3+ , 3+ indicate strong positivity . Fluorescence In Situ Hybridization ( FISH ) analyse also perform patient . Patients 2+ 3+ overexpression HER2/neu ( membranous stain ) eligible , regardless result FISH analysis . Age ≥18 year . Karnofsky performance status ≥ 60 % . Adequate hepatic , renal , hematologic function . Prior treatment trastuzumab allow . All patient must adequate cardiac function ( define leave ventricular ejection fraction ≥ 45 % ) document echocardiogram MUGA scan . Premenopausal woman require negative urine serum pregnancy test use effective form contraception . Patients history brain metastasis permit long least 30 day since definitive treatment , clinically stable magnetic resonance image scan brain demonstrates control lesion ( ) . All patient must give write informed consent indicate aware investigational nature treatment , well risk benefit protocol . No treatment chemotherapy trastuzumab allow within four week study entry . Prior therapy vinorelbine . Known history hypersensitivity trastuzumab , Chinese hamster ovary ( CHO ) cell protein , component product . History current unstable angina , symptomatic congestive heart failure , myocardial infarction within last 6 month . Pregnant woman exclude . History known hypersensitivity E. coliderived protein , filgrastim , component product .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Her-2/neu</keyword>
	<keyword>Granulocyte Colony Stimulating Factor</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Vinorelbine</keyword>
	<keyword>Antibody-dependent cellular cytotoxicity</keyword>
	<keyword>Effector cell</keyword>
</DOC>